(MedPage Today) — The FDA approved navepegritide (Yuviwel) for children ages 2 and older with achondroplasia, the most common form of dwarfism, developer Ascendis Pharma announced on Friday.
The prodrug of C-type natriuretic peptide (CNP) is…
Source link : https://www.medpagetoday.com/endocrinology/growthdisorders/120113
Author :
Publish date : 2026-03-02 19:09:00
Copyright for syndicated content belongs to the linked Source.
